The estimated Net Worth of James C Gale is at least $251 Milión dollars as of 31 May 2019. James Gale owns over 20,000 units of Pfenex stock worth over $223,278,259 and over the last 18 years James sold PFNX stock worth over $27,914,234.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
James Gale PFNX stock SEC Form 4 insiders trading
James has made over 6 trades of the Pfenex stock since 2014, according to the Form 4 filled with the SEC. Most recently James bought 20,000 units of PFNX stock worth $13,200 on 31 May 2019.
The largest trade James's ever made was selling 1,907,767 units of Pfenex stock on 29 April 2015 worth over $27,796,165. On average, James trades about 147,415 units every 110 days since 2006. As of 31 May 2019 James still owns at least 394,624 units of Pfenex stock.
You can see the complete history of James Gale stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's James Gale's mailing address?
James's mailing address filed with the SEC is CARNEGIE HALL TOWER, 152 W 57TH STREET 19TH FLOOR, NEW YORK, NY, 10019.
Insiders trading at Pfenex
Over the last 10 years, insiders at Pfenex have traded over $99,496,796 worth of Pfenex stock and bought 36,000 units worth $174,640 . The most active insiders traders include Chemical Co /De/ Dow, James C Gale a Healthcare Partners Accredi.... On average, Pfenex executives and independent directors trade stock every 46 days with the average trade being worth of $90,240,574. The most recent stock trade was executed by Asset Management Lpweiss An... on 29 September 2020, trading 100,000 units of PFNX stock currently worth $1,274,000.
What does Pfenex do?
Pfenex, Inc. is a development and licensing Biotechnology Company, which focuses on leveraging its Pfenex Expression Technology platform for developing and improving protein therapies. Its products include PF708, PF743, PF745, CRM197, PF810, PF753 and PFXX. The company was founded on November 19, 2009 and is headquartered in San Diego, CA.
What does Pfenex's logo look like?
Complete history of James Gale stock trades at Teligent Inc a Pfenex
Pfenex executives and stock owners
Pfenex executives and other stock owners filed with the SEC include:
-
Shawn Scranton,
Chief Operating Officer -
Susan A. Knudson,
Chief Financial Officer -
Evert B. Schimmelpennink,
See Remarks -
Patricia Lady,
Chief Accounting Officer -
Jason Grenfell Gardner,
Director -
Martin Brenner,
Chief Scientific Officer -
Magda Marquet,
Director -
Phillip M Schneider,
Director -
Sigurdur O Olafsson,
Director -
Hubert C Chen,
Chief Medical Officer -
John Mack Taylor,
Director -
Patrick K. Lucy,
Chief Business Officer -
Robin Campbell,
Director -
Lorianne Masuoka,
Director -
Dennis M Fenton,
Director -
William R Rohn,
Director -
Henry W. Jr. Talbot,
VP of Research & Operations -
Healthcare Partners Accredi...,
10% owner -
Bertrand C. Liang,
Chief Executive Officer -
Steven S. Sr. Sandoval,
Chief Manufacturing Officer -
Paul A. Wagner,
Chief Financial Officer -
Chemical Co /De/ Dow,
10% owner -
Healthcare Partners Accredi...,
-
James C Gale,
Director -
Asset Management Lpweiss An...,
-
Management, Llc Newtyn,
10% owner